Steeleyeye is correct and you are playing with semantics here and possibly tiptoeing a bit, with subpar theatrical acting on your part. He must be admiring your subtleties, KLMNOP. And you're just doing your job since you have a vested interest in the company. That's fair enough.
First of all, Brilacidin is not Purisol.
Not a textbook play? I'm sorry, but the two drugs are entirely different compounds, with different MoA, and zero correlation to what clinical patients they are trying to address. Let me opine, and you can feel free to REPEAT THIS AFTER ME and say,
Purisol is a sunk cost. It's neither here nor there. They are two independent events!
Everybody knows that, correct?
The fact is, Brilacidin is a clinical drug that's been at least proven as safe and effective beyond midstage clinical trials!
It's been tested in 507 patients and potentially a groundbreaking therapeutic and prophylaxis drug in combating the covid19. It has the potential to address all flu pandemics ( and it will again : ) ) and not to mention other inflammatory disease and/or head and neck cancer.
Bril worked in two of three different epithelial cells that are involved and affected by the SARS-CoV virus. And the last validation of lung results with its p-value? That is highly likely to translate into a successful outcome in human clinical trials whether you believe it's 80% chances of failing or a 100% probability of success like what I'd think it will do. But that just my opinion.
What the bulls or bears wish to believe is up to them. The results in two human epithelial cells were simply astonishing, I must say. Did you see it coming?
Bril drug will be repurposed for the Phase II trial and more likely across all stages of Cv19 patients with grants and/or Private placement funding. There's no doubt in my mind that Bril will succeed with endpoints set so low. What you believe or how to wish to profit on that information is up to you.
Best of luck to you if you are betting against this Brilacidin drug company. It's your money. I'd go bullish if you haven't already! Our next stop is a Phase II milestone and it's valuation. I sense a $600+ mil valuation backed up with at least one phase II in moderate CV19 trial patients plus a small grant funding is very attainable.
